Overview

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Status:
Completed
Trial end date:
2021-06-23
Target enrollment:
Participant gender:
Summary
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer